- Predictive Oncology Inc. (POAI) will effect a **1-for-15 reverse stock split** of its common stock, which was approved by stockholders at a special meeting on **September 19, 2025**.  **[1446159_0001171843-25-006069_exh_31.htm:0]** **[1446159_0001171843-25-006069_exh_991.htm:0]** **[1446159_0001171843-25-006069_f8k_092525.htm:1]** **[1446159_0001171843-25-006069_f8k_092525.htm:2]** 
- The primary purpose of the reverse stock split is to bring the company into compliance with the **Nasdaq minimum bid price requirement** to maintain its listing on the Nasdaq Capital Market.  **[1446159_0001171843-25-006069_exh_991.htm:0]** **[1446159_0001171843-25-006069_exh_991.htm:1]** 
- The reverse stock split will become effective on **September 29, 2025, at 5:00 PM ET**, with the common stock beginning to trade on a split-adjusted basis on **September 30, 2025**.  **[1446159_0001171843-25-006069_exh_31.htm:0]** **[1446159_0001171843-25-006069_exh_991.htm:0]** **[1446159_0001171843-25-006069_f8k_092525.htm:1]** 
- Prior to the split, there were **11,436,201** shares of common stock outstanding; immediately following the split, there will be approximately **762,414** shares outstanding, subject to adjustment for the rounding up of fractional shares.  **[1446159_0001171843-25-006069_exh_991.htm:0]**

Predictive Oncology Announces 1-for-15 Reverse Stock Split

- Predictive Oncology Inc. (POAI) entered into a Securities Purchase Agreement on **August 26, 2025**, for a private placement.  **[1446159_0001171843-25-005680_f8k_082625.htm:1]** 
- The company sold **543,544 shares** of its common stock at a purchase price of **$0.76 per share**.  **[1446159_0001171843-25-005680_f8k_082625.htm:1]** 
- The offering generated approximately **$413,093** in gross proceeds, which will be used for **working capital and general corporate purposes**.  **[1446159_0001171843-25-005680_f8k_082625.htm:1]** 
- As part of the agreement, the company has agreed to certain restrictions on future common stock issuances and granted the investor a 100% participation right in future equity offerings through **October 31, 2025**.  **[1446159_0001171843-25-005680_f8k_082625.htm:1]**

Predictive Oncology (POAI)